NEW YORK (360Dx) – With the recent launch of its mass spectrometry RenataDx Screening System, Waters is looking to reinforce its position in the newborn screening market and serve growing demand for newborn screening in the developing world.

The company introduced the system last month. Combining Waters' Xevo TDQ IVD mass spec, ACQUITY UPLC I-Class IVD Binary Solvent Manager, and the 3777C IVD Sample Manager along with the company's MassLynx and IonLynx software, the platform uses flow-injection tandem mass spec to enable high-throughput analysis of dried blood spots.